

Mélanie Caron

De: Susan Cowan [REDACTED]
Envoyé: 26 février 2021 11:53
À: Mélanie Caron; Martine Perreault
Cc: Kate Lee; Angie Specic; Helen Culbert
Objet: Follow up meeting re: Biosimilar switch



Message automatisé : Ce courriel provient de l'extérieur de votre organisation. Ne cliquez pas sur les liens et pièces jointes si vous ne reconnaissez pas l'expéditeur.

Dear Ms. Caron,

I am Sue Cowan, the interim CEO of Crohn's and Colitis Canada. I hope this email finds you well.

I am following up on a meeting held with Crohn's and Colitis Canada's former President & CEO – Mina Mawani – and yourself on Quebec's consideration of implementing a biologic to biosimilar switch policy.

We understand that the Quebec government has been contacting gastroenterologists and other patient organizations to re-initiate consultations leading up to the government's switch policy.

As Mina mentioned, Crohn's and Colitis Canada is the only national health charity focused on research and supporting Crohn's disease and ulcerative colitis patients through education, awareness and advocacy. In preparation for our follow up meeting, we held a roundtable of gastroenterologists and patients and have conducted surveys.

To support Quebec's decision on the switch policy, we are reaching out to request a meeting with you and/or Ms. Perreault at your earliest convenience to share this information.

We hope to work with you to support cost savings along with ensuring the health of Quebec constituents living with Crohn's disease and ulcerative colitis. We are looking forward to hearing from you.

Sincerely,

Sue

Susan Cowan
Chief Executive Officer
Crohn's and Colitis Canada
600 - 60 St. Clair Ave. E., Toronto ON M4T 1N5
T: 416-920-5035 x 222 | C: 416-629-0080
Get Gutsy: [Learn](#) | [Volunteer](#) | [Donate](#)